We downgrade our rating on EBOS Group (EBO) to NEUTRAL from OUTPERFORM on valuation grounds. The recent Pharmaceutical Wholesaler Agreement (PWA) has driven a re-rating in EBO's share price.
What is covered in the Full Insight:
Introduction
Valuation and Rating Downgrade
Earnings and Target Price Update
Market Pricing and Comparisons
Outlook and Upcoming Results
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.